Literature DB >> 3003144

Opioid modulation of normal and pathological human chromaffin tissue.

M Mannelli, M Maggi, M L DeFeo, M Boscaro, G Opocher, F Mantero, E Baldi, G Giusti.   

Abstract

To evaluate whether opioid receptor blockade might modulate sympathetic-adrenal activity, we studied the effects of placebo or naloxone administration on plasma catecholamine (CA) levels in a group of 13 normal subjects and 15 hypertensive patients suspected to have a pheochromocytoma. Diagnostic evaluation confirmed the presence of pheochromocytoma in 9 patients. Among these, 4 had a unilateral epinephrine (E)-secreting tumor, 3 had bilateral E-secreting tumors due to multiple endocrine adenomatosis type IIa, and 2 had a unilateral norepinephrine (NE)-secreting tumor. In each subject studied, CA secretion was evaluated by calculating the area (0-30 min) under the plasma hormone curves after placebo or naloxone administration. In normal subjects naloxone caused a significant increase (P less than 0.005) of E secretion, whereas NE did not change. Similarly, in the group of hypertensive patients, E secretion increased after naloxone (P less than 0.01). In pheochromocytoma patients naloxone caused a significant increase in E (P less than 0.05) and NE (P less than 0.01) secretion from E-producing tumors but no increase in the patients with NE-secreting pheochromocytomas. The study suggests that CA secretion from normal and pathological chromaffin tissue is modulated by endogenous opioids; this modulation seems particularly evident in patients with E-secreting pheochromocytoma.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3003144     DOI: 10.1210/jcem-62-3-577

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  7 in total

Review 1.  Diagnostic problems in pheochromocytoma.

Authors:  M Mannelli
Journal:  J Endocrinol Invest       Date:  1989-11       Impact factor: 4.256

Review 2.  Dynorphins in Development and Disease: Implications for Cardiovascular Disease.

Authors:  Cody Cissom; Jason J Paris; Zia Shariat-Madar
Journal:  Curr Mol Med       Date:  2020       Impact factor: 2.222

3.  Evaluation of clonidine suppression and various provocation tests in the diagnosis of pheochromocytoma.

Authors:  H Koshida; I Miyamori; R Soma; T Matsubara; S Okamoto; M Ikeda; R Takeda
Journal:  J Endocrinol Invest       Date:  1990-11       Impact factor: 4.256

Review 4.  Adverse drug reactions in patients with phaeochromocytoma: incidence, prevention and management.

Authors:  Graeme Eisenhofer; Graham Rivers; Alejandro L Rosas; Zena Quezado; William M Manger; Karel Pacak
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

Review 5.  Chromaffin cell biology: inferences from The Cancer Genome Atlas.

Authors:  Lauren Fishbein; Matthew D Wilkerson
Journal:  Cell Tissue Res       Date:  2018-02-15       Impact factor: 5.249

6.  Measurement of catecholamines, met-enkephalin, somatostatin and substance P-like immunoreactivities in 12 human pheochromocytomas.

Authors:  E Baldi; M L De Feo; P Geppetti; V Carlà; M Maggi; C Pupilli; M G Spillantini; A Brocchi; M Mannelli
Journal:  J Endocrinol Invest       Date:  1988-02       Impact factor: 4.256

7.  Opioid Receptor Activation Impairs Hypoglycemic Counterregulation in Humans.

Authors:  Michelle Carey; Rebekah Gospin; Akankasha Goyal; Nora Tomuta; Oana Sandu; Armand Mbanya; Eric Lontchi-Yimagou; Raphael Hulkower; Harry Shamoon; Ilan Gabriely; Meredith Hawkins
Journal:  Diabetes       Date:  2017-08-31       Impact factor: 9.461

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.